About the Company
GeoVax is a clinical-stage biotechnology company which develops vaccines. GeoVax's development platform uses Modified Vaccinia Ankara (MVA) vector technology, with improvements to antigen design and manufacturing capabilities. GeoVax uses recombinant DNA or recombinant viruses to produce virus-like particles (VLPs) in the person being vaccinated.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $GOVX News
GeoVax Labs, Inc. (GOVX)
Presentation Made During the 24th Annual World Vaccine CongressATLANTA, GA - (NewMediaWire) - April 04, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies ...
GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine
ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious ...
GeoVax Labs gets grant for recombinant MVA vector for generating immune response to hemorrhagic viruses
Discover how GeoVax Labs Inc's patented MVA vector technology targets deadly hemorrhagic fever viruses like ebolavirus and Marburgvirus, offering both preventive and therapeutic benefits.
GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress
ATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and ...
Geovax Labs Inc GOVX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
GeoVax, Inc.: GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine
ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious ...
GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress
GEO-CM04S1 is currently being evaluated in three ongoing Phase 2 clinical trials: GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor ...
GeoVax Labs Inc (GOVX)
ATLANTA - GeoVax Labs, Inc. (NASDAQ:GOVX), a biotech firm focused on developing vaccines for infectious diseases and cancer immunotherapies, announced at the 24th Annual World ...
GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine
via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chief ...
GeoVax Labs Inc (GOVX)
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like ...
GeoVax Labs, Inc. (GOVX)
Presentation Made During the 24th Annual World Vaccine Congress ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing ...
Loading the latest forecasts...